Vimarsana
Biggest News Aggregation in the World

Page 3 - Chris Pak News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Chris Pak. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Chris Pak Today - Breaking & Trending Today

Molecular Targeting Technologies, Inc. and University of Antwerp Begin First-in-Human Study of TDURA Diagnostic for Early Detection of Response to Colon Cancer Therapy - Vimarsana News

Molecular Targeting Technologies, Inc. and University of Antwerp Begin First-in-Human Study of TDURA Diagnostic for Early Detection of Response to Colon Cancer Therapy

Published: May 11, 2021     WEST CHESTER, Pa.--(BUSINESS WIRE)-- Molecular Targeting Technologies, Inc.   (MTTI) and University of Antwerp today announced the approval of a Clinical Trial Application by the European Federal Agency for Medicines and Health Products (FAMHP) (equivalent to a US IND). The clinical study will evaluate the safety, dosimetry and treatment response of TDURA ( 99mTc-Duramycin), in patients with advanced colorectal cancer (CRC)*. Colorectal cancer is the third most commonly diagnosed malignancy in the world and the second leading cause of cancer death in the Un...

FDA Approves Investigational New Drug (IND) for Neuroendocrine Tumors from Molecular Targeting Technologies, Inc. - Vimarsana News

FDA Approves Investigational New Drug (IND) for Neuroendocrine Tumors from Molecular Targeting Technologies, Inc.

Press release content from Business Wire. The AP news staff was not involved in its creation. FDA Approves Investigational New Drug (IND) for Neuroendocrine Tumors from Molecular Targeting Technologies, Inc. March 2, 2021 GMT WEST CHESTER, Pa.--(BUSINESS WIRE)--Mar 2, 2021-- Molecular Targeting Technologies, Inc. (MTTI), a clinical stage radiopharmaceutical therapy company focused on therapies for rare diseases, announced today the approval of an Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA). It enables a Phase I clinical study of the Safety and Dos...

Source: apnews.com